Chonluten
A synthetic tripeptide bioregulator (Glu-Asp-Gly) from the Khavinson system, studied for respiratory and bronchial mucosal health, anti-inflammatory gene regulation, and stress protection in lung tissue.
Chonluten is a three-amino-acid peptide (Glu-Asp-Gly) from the Russian Khavinson bioregulator programme, sold as a respiratory supplement. The evidence behind that positioning is thinner than it appears: searching PubMed for 'chonluten' returns exactly one paper, a cell-culture experiment, and the respiratory claims about chronic bronchitis come from the group's own review articles with no patient numbers or trial design ever published. Oddly, the Khavinson programme's own classification table lists this peptide as a gastroprotector rather than a respiratory one, and its single indexed animal study is a rat stomach-ulcer model. Nothing about it has been replicated outside that one research group.
What is Chonluten?
Chonluten is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in bronchial and lung tissue. Its principal biological target is the respiratory system, specifically the bronchial mucosa and lung epithelium. It is often discussed alongside Bronchogen (AEDL), which targets deeper lung tissue and cell differentiation, while Chonluten is more associated with stress-protective and anti-inflammatory gene regulation in respiratory epithelium.
What Chonluten Is Investigated For
Chonluten is a Khavinson-program tripeptide investigated for bronchial and respiratory mucosal health, anti-inflammatory gene regulation in lung tissue, adjunct support for chronic bronchitis and COPD, and stress protection under low-oxygen conditions. The strongest mechanistic evidence is a single peer-reviewed in vitro study in THP-1 monocytes showing that the Glu-Asp-Gly sequence inhibits TNF production under LPS stimulation, alongside molecular docking work predicting LAT1 and PEPT1 transporter-mediated uptake. There is also a complication the respiratory framing tends to obscure: within the Khavinson programme's own publications, EDG is classified as a gastroprotector and stress protector rather than a respiratory agent, and the only indexed primary animal study of the peptide is a rat gastric-ulcer model. The central honest caveat is that clinical evidence is thin and doubly confounded: the Russian clinical findings credited to Chonluten (in chronic bronchitis with an asthmatic component and under low oxygen) are known only from Khavinson-group review summaries without published study designs, and no randomized controlled trials are indexed in Western databases. Independent Western replication of the gene-regulation claims is absent, and the proposed mechanism of direct DNA interaction by a tripeptide remains debated. Chonluten is not FDA-approved, not a dietary-supplement ingredient, and should not substitute for evidence-based management of COPD, asthma, or chronic bronchitis.
History & Discovery
Chonluten emerged from the same Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology that produced the broader Cytogen / Cytomax bioregulator series. It was developed as a synthetic short-peptide counterpart to bronchial-tissue extracts, with the active sequence reduced to the tripeptide Glu-Asp-Gly (EDG, also designated T-34 in some Khavinson-group publications). Within the bioregulator framework it is positioned alongside Bronchogen (AEDL, a tetrapeptide), with Bronchogen aimed at deep lung epithelial differentiation and Chonluten aimed more at stress-protective and anti-inflammatory gene programs in bronchial mucosa. Chonluten's published footprint is real but small: a handful of in vitro studies in monocyte/macrophage models showing TNF and IL-6 suppression, molecular docking work supporting LAT1 transporter-mediated cellular uptake, and a Russian-language clinical literature on chronic bronchitis and asthmatic-component bronchitis known mainly through Khavinson-group review summaries rather than indexed trial reports. As with the rest of the Khavinson lineup, the work is concentrated within a single research orbit, has not been independently replicated in Western laboratories, and has not generated controlled clinical trial data for any defined respiratory indication.
How It Works
Chonluten is a tiny three-amino-acid peptide proposed to enter lung and bronchial cells, where it helps regulate genes involved in stress defense and inflammation. It may help the respiratory system manage oxidative stress and inflammatory responses by boosting protective gene programs — particularly those encoding antioxidant enzymes and heat-shock proteins.
Chonluten (Glu-Asp-Gly) is proposed to penetrate cell membranes due to its small molecular size and interact with DNA regulatory regions in respiratory epithelial cells. Molecular modeling suggests high affinity for the LAT1 amino acid transporter (ICM-Score: -30.30), providing a plausible cellular uptake mechanism. The Khavinson group's COVID-era review states that the stress-protective effect of the EDG tripeptide is associated with regulating expression of c-Fos, the heat-shock protein gene HSP70, the antioxidant enzyme gene SOD, COX-2 and TNF-alpha. That list is widely repeated, including by vendors, but it appears as a review assertion with a single onward citation rather than as a primary result, and the one indexed primary study of EDG gene regulation is a rat gastric-ulcer model measuring HSP70, nitric oxide synthase I and II, and NF-kB RelA — an overlapping but not identical set, in the stomach rather than the lung. In the one monocyte/macrophage cell-line study, Chonluten inhibited TNF production in LPS-stimulated cells. Two other effects often attributed to Chonluten from that same paper belong to the whole panel rather than to this peptide: IL-6 suppression and reduced monocyte adhesion to activated endothelium were reported for all the peptides tested, with Thymogen the most effective on adhesion. Chonluten was distinctive in that study for something else entirely — it roughly doubled apoptosis in treated cells relative to the other peptides. Transport is modelled rather than measured. Docking work gives EDG a strong predicted affinity for LAT1 (ICM-Score -30.30, second only to the dipeptide ED in that table), and a later paper from the same group adds PEPT1 — the canonical intestinal di- and tripeptide transporter, and mechanistically the more apt carrier for an orally dosed tripeptide. Neither has been validated in cells or in vivo.
Evidence Snapshot
Human Clinical Evidence
Very limited. Observational clinical data from the Khavinson program suggests oral Chonluten enhanced the effectiveness of standard therapy in patients with chronic bronchitis with an asthmatic component and improved physical performance under low-oxygen conditions. However, these findings are known only from Khavinson-group review summaries; the underlying studies are not indexed in PubMed and their design is unpublished. No randomized controlled trials are indexed in Western databases.
Animal / Preclinical
Thin, and thinner than it looks. There is exactly one indexed primary animal study of the EDG tripeptide: a rat gastric-ulcer model (PMID 22803148) reporting regulation of HSP70, nitric oxide synthase I and II, and NF-kB RelA. The anti-inflammatory signal most often cited for Chonluten is not animal work at all but a single in vitro experiment in the THP-1 monocyte line, and the gene list usually attributed to it — c-Fos, HSP70, SOD, COX-2 and TNF-alpha — comes from a review paragraph rather than from a primary paper this directory has been able to locate. Molecular modeling predicts, rather than confirms, LAT1 and PEPT1 transporter binding; no uptake has been measured in cells or in vivo.
Mechanistic Rationale
Moderate, with an important qualification about which effects are actually specific to this peptide. In the THP-1 experiment, the TNF suppression under LPS was reported for Chonluten specifically, but the IL-6 suppression and the reduced monocyte adhesion were reported for all the peptides tested, and Thymogen rather than Chonluten was the standout on adhesion. The one thing Chonluten did uniquely in that study was double apoptosis in treated cells relative to the other peptides. The proposed mechanism of gene regulation through direct DNA interaction comes from the broader Khavinson short-peptide program and has not been independently replicated outside it.
Research Gaps & Open Questions
What the current literature has not yet settled about Chonluten:
- 01Independent replication outside the Khavinson research program — the in vitro TNF/IL-6 suppression and the proposed bronchial-epithelial gene regulation have not been verified by Western respiratory-immunology laboratories.
- 02Indexed clinical trials — the Russian clinical findings credited to Chonluten are known only from Khavinson-group review summaries, with no peer-reviewed trial report, patient numbers or registered protocol.
- 03Human pharmacokinetics — oral, sublingual, and parenteral bioavailability of the EDG tripeptide in humans is uncharacterized, and the LAT1 and PEPT1 transporter binding hypotheses are docking predictions that have never been validated in cells or in vivo.
- 04Which organ system this peptide actually belongs to. The Khavinson programme markets it for the respiratory tract, classifies it in its own transporter table as a gastroprotector and stress protector, and has published its only indexed primary animal study in a rat gastric-ulcer model. No experiment has directly compared EDG's effects in respiratory versus gastric tissue.
- 05Blinded randomized controlled trials in COPD or chronic bronchitis — the existing Russian clinical reports do not meet modern RCT-methodology standards and lack independent replication.
- 06Long-term safety in inflammatory lung disease — chronic anti-inflammatory gene modulation in respiratory epithelium has not been studied for off-target effects.
- 07Comparative efficacy versus first-line respiratory pharmacotherapy — no head-to-head studies against inhaled corticosteroids, LABA/LAMA combinations, or biologics exist.
Forms & Administration
Chonluten is available as oral capsules and sublingual drops. Capsule protocols typically involve 1-2 capsules daily for 10-30 days, with courses repeated 2-3 times per year. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Khavinson-line oral capsules contain on the order of 200 mcg of peptide per capsule, dosed as 1–2 capsules per day. Sublingual drop formulations are also sold and dosed in comparable cumulative ranges. Injectable Chonluten via research-chemical channels, where used, follows the standard bioregulator convention of 100–200 mcg subcutaneously per dose.
Frequency
Once daily during a course is the standard cadence, occasionally split into morning and evening for the oral capsule and drop formulations.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10-day courses repeated 2–3 times per year is the canonical Khavinson schedule. Some bronchopulmonary protocols extend a single course to 20–30 days. Continuous chronic dosing is not part of the published convention.
Protocol Notes
Chonluten is overwhelmingly an oral and sublingual product in commercial reality, sold under the Khavinson Peptides brand in Russia as a respiratory-support functional food. The published Russian clinical experience is known only from review summaries, so even where some clinical signal exists, its size and reliability cannot be checked. Reconstitution for the rare injectable form follows the standard bioregulator convention: 5 mg of lyophilized peptide into 1–2 mL of bacteriostatic water, dosed on an insulin syringe. No Western clinician operates a Chonluten protocol for COPD, chronic bronchitis, or any other respiratory condition; any cadence you encounter outside Russia is forum or vendor convention rather than independently anchored guidance.
Chonluten is not FDA-approved for any indication. Respiratory and anti-inflammatory claims significantly exceed what controlled clinical evidence supports. It should not substitute for evidence-based management of COPD, asthma, chronic bronchitis, or any other pulmonary condition by a qualified clinician.
Timeline of Effects
Onset
No characterized onset profile from controlled clinical work. The proposed mechanism (transcriptional modulation of stress-response and anti-inflammatory gene programs) is structural and slow in concept, not acutely symptomatic. Russian clinical reports measure outcomes at the end of a course rather than tracking acute onset.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–20 day course. Improvements in physical performance under low-oxygen conditions and in chronic-bronchitis symptom scores have been described at end-of-course assessments, though only in Khavinson-group review summaries without published trial details.
After Discontinuation
No documented withdrawal or rebound. The framework's standard claim is gene-expression remodeling persisting after dosing ends, but for Chonluten specifically this persistence has not been independently verified.
Common Questions
What is the difference between Chonluten and Bronchogen?
Both are Khavinson bioregulator peptides targeting the respiratory system, but they address different aspects. Chonluten (EDG, a tripeptide) is more associated with stress-protective and anti-inflammatory gene regulation in bronchial mucosa — modulating genes like c-Fos, HSP70, SOD, COX-2, and TNF-alpha. Bronchogen (AEDL, a tetrapeptide) targets lung cell differentiation and epithelial maintenance, regulating genes like NKX2-1, MUC4, and MUC5AC. Vendors often sell them as a pair, though no published study has tested the combination.
Can Chonluten be taken orally?
Yes. As a tripeptide of only three amino acids, Chonluten is small enough for oral absorption. Molecular modeling studies suggest it can be transported into cells via LAT1 transporters. It is available as oral capsules and sublingual drops.
Is Chonluten FDA-approved?
No. Chonluten is not FDA-approved and is not used in mainstream Western medicine. Clinical data comes primarily from Russian research institutions associated with the Khavinson bioregulator program. No published randomized controlled trials are indexed in Western databases.
Is there real evidence Chonluten helps with COPD or chronic bronchitis?
Not by Western evidence standards. The published Russian clinical experience in chronic bronchitis with an asthmatic component is summarized in Khavinson-group reviews as Chonluten improving the results of standard therapy, without published patient numbers or trial design, which is far short of demonstrating a treatment effect. No randomized controlled trials are indexed in Western databases, and the in vitro TNF and IL-6 suppression in THP-1 monocytes has not been shown to translate to clinically meaningful pulmonary anti-inflammatory effect in humans. Chonluten should not substitute for evidence-based management of COPD, asthma, or chronic bronchitis.
Is Chonluten the same thing as peptide T-34?
Yes. T-34 is the Khavinson programme's internal designation for the Glu-Asp-Gly tripeptide, confirmed directly in a 2012 paper that lists the series as T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). This matters for anyone trying to check the evidence themselves: searching PubMed for 'chonluten' returns a single paper, but searching for T-34 surfaces the primary Russian work, including the rat gastric-ulcer gene-regulation study that is the peptide's only indexed animal experiment. Most of what is written about Chonluten online is indexed under a name the research literature does not use.
Why is Chonluten often paired with Bronchogen?
Within the Khavinson framework the two peptides are positioned as complementary respiratory bioregulators — Chonluten (EDG) for stress-protective and anti-inflammatory gene programs in bronchial mucosa, Bronchogen (AEDL) for deeper lung epithelial differentiation and maintenance. Khavinson's group also reports finding both in the same bronchial peptide preparation (Langopept), and vendors often sell them together. No published study has tested the pair, and the clinical findings the group's reviews cite for chronic bronchitis and low-oxygen performance are credited to EDG itself, not to a combination.
Who Chonluten Is NOT For
- •Active or recent malignancy involving lung or bronchial tissue — gene-modulating peptides have not been characterized for safety in pulmonary oncology contexts.
- •Acute respiratory infection requiring evaluation — Chonluten should not delay or substitute for antibiotics, antivirals, or other indicated acute care.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data; pulmonary developmental signaling effects unknown.
- •Known hypersensitivity to peptide preparations or to capsule and sublingual-drop excipients in commercial Khavinson-line products.
Drug & Supplement Interactions
There are no documented clinical drug interactions for Chonluten because no human pharmacovigilance studies of meaningful scale exist. What follows is theoretical. The most plausible concerns are with corticosteroids and other anti-inflammatory regimens used in COPD and asthma management. Chonluten's claimed suppression of TNF, IL-6, and COX-2 signaling could in theory layer additively or in unpredictable ways onto inhaled or systemic corticosteroids, leukotriene modifiers, or biologics targeting Th2 inflammation — none of which has been formally studied. A second concern applies to immunosuppressed patients on transplant or autoimmune-disease regimens, where any agent claimed to broadly modulate inflammatory gene expression could, in principle, complicate immunosuppression management. No CYP-mediated interactions are described, and at the small doses involved, pharmacokinetic interactions at the metabolism level are unlikely. Patients on respiratory or immunosuppressive medications should disclose Chonluten use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Clinical data is limited and primarily from Russian research
- • No formal toxicology or pharmacokinetic studies meeting Western regulatory standards
- • No drug interaction studies have been conducted
- • Quality and purity vary by source
What We Don't Know
Western clinical trial data is absent. No dose-escalation studies, formal toxicology, or independent pharmacokinetic data exist. The claimed mechanism of direct DNA interaction by a tripeptide remains debated in the broader scientific community. Long-term safety has not been evaluated in controlled studies.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient and not on the FDA's compounding-eligible peptide list. Available primarily as personally imported Russian-market oral product or via research-chemical injectable channels, neither of which is an authorized clinical pathway.
International
Sold in Russia under the Peptides.ru / Khavinson Peptides brand as an oral peptide bioregulator capsule and sublingual drop, positioned as a dietary supplement / functional food rather than a registered prescription medicine. Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because no governmental regulatory health authority approves Chonluten for human therapeutic use, injectable Chonluten can reasonably be read as falling under WADA's S0 catch-all category. Athletes subject to WADA code should treat injectable Chonluten as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Chonluten is a respiratory peptide.
Reality
That is how it is sold, but the Khavinson programme's own publications are not consistent on it. The group's transporter paper classifies EDG as a gastroprotector and stress protector, and reserves the label bronchoprotector for Bronchogen (AEDL); the body text of that paper names EDG specifically as a gastroprotector. The only indexed primary animal study of the peptide is a rat gastric-ulcer model. The respiratory positioning comes from the group's review articles, which do describe EDG as effective in bronchopulmonary pathology and derived from bronchial epithelial cells — so it is not invented, but it rests on review assertions rather than on EDG-specific respiratory data, and it sits awkwardly beside the group's own classification.
Myth
The THP-1 study shows Chonluten is a uniquely potent anti-inflammatory.
Reality
It shows something more modest. In that experiment several Khavinson peptides were tested together, and the IL-6 suppression and the reduction in monocyte adhesion were reported for all of them rather than for Chonluten specifically — Thymogen, not Chonluten, was the standout on adhesion. The TNF result is the one Chonluten-specific finding. The thing Chonluten did uniquely was double the level of apoptosis in treated cells compared with the other peptides, which is not obviously a benefit and is not mentioned in any vendor material.
Myth
Chonluten is a treatment for COPD.
Reality
It is not approved as a treatment for COPD by any regulatory body and there are no controlled trials supporting it as a COPD therapy. Russian clinical literature describes it as improving the results of standard care in chronic bronchitis with an asthmatic component, which is far short of demonstrating it treats COPD.
Myth
Chonluten and Bronchogen are interchangeable.
Reality
The Khavinson framework explicitly distinguishes them — EDG (Chonluten) for stress-protective and anti-inflammatory gene regulation in bronchial mucosa, AEDL (Bronchogen) for deeper lung epithelial differentiation. Whether that distinction holds biologically is itself a research gap, but they are not marketed or used as substitutes for one another.
Myth
Because Chonluten is small enough for oral and sublingual absorption, the systemic exposure is essentially the same as injection.
Reality
Oral, sublingual, and parenteral bioavailability of EDG have not been measured comparatively in humans. Tripeptides may resist intestinal degradation, but resistance to degradation is not the same as quantified systemic exposure to lung tissue.
Myth
The in vitro TNF and IL-6 suppression translates directly to clinically meaningful anti-inflammatory effect in the lungs.
Reality
Cell-line experiments in THP-1 monocytes are mechanistically informative but routinely fail to predict clinical anti-inflammatory benefit at achievable in vivo concentrations. No bronchoalveolar lavage or pulmonary biomarker data in humans supports the in vitro signal translating to clinical effect.
Myth
Chonluten is a form of inhaled therapy.
Reality
It is not. All commercial Khavinson-line Chonluten products are oral capsules or sublingual drops, and where injectable forms exist through research-chemical channels they are for subcutaneous use, not inhaled. No inhaled Chonluten preparation has been developed or published — reaching lung tissue with a systemically dosed tripeptide requires bioavailability and distribution that have not been demonstrated in humans by independent work.
Published Research
6 studiesFeasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Peptides: Prospects for Use in the Treatment of COVID-19
Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins
Khavinson VKh, Lin'kova NS, Dudkov AV, Polyakova VO, Kvetnoi IM, Bull Exp Biol Med 2012. The only indexed primary animal study of the EDG tripeptide, and notably it is not a respiratory one: a rat gastric-ulcer model, indexed under gastric mucosa, stomach ulcer and Helicobacter pylori, measuring HSP70, nitric oxide synthase types I and II, and NF-kB RelA. The abstract reports that peptide T-34 normalises synthesis of antioxidant and anti-inflammatory proteins by regulating expression of the corresponding genes.
Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats
Voicekhovskaya MA, Chalisova NI, Kontsevaya EA, Ryzhak GA, Bull Exp Biol Med 2012. The paper that establishes what 'T-34' means, naming the series explicitly as T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). It also carries the programme's most useful negative result for this peptide: in skin explants from young rats, every tripeptide in the series except T-34 stimulated cell proliferation.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Oct 2026
- Citations
- 6PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.